The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on acute sexual arousal and sexual interest in post menopausal females, as well as examining the safety and toleration of the drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
23
Single 200mg dose
Pfizer Investigational Site
Kobenhavn OE, Denmark
Pfizer Investigational Site
Oslo, Norway
Pfizer Investigational Site
Danderyd, Sweden
Assess effect of single doses of PF-00446687 on acute sexual arousal and sexual interest, using questionnaires, in post menopausal women suffering from Female Sexual Dysfunction. A diary will be completed for 7 days following the 3 dosing days.
Time frame: From day of dosing until 7 days post-dose
Assess effect of single doses on medium term (1 week) sexual arousal and interest.
Time frame: Until 7 days post-dose
Assess variability of response and repeatability of design between 2 similar doses.
Time frame: Comparison of response to be assessed until 7 days post dose
If possible assess the effect of PF-00446687 on vaginal blood flow on day 1 of each study period.
Time frame: Day of dosing
Assess PK , safety and toleration on day 1 of each study period.
Time frame: Day of dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.